These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20394542)

  • 41. Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment.
    Romero-Díaz de León L; Morales-León JE; Ledesma-Gil J; Navas A
    Int Ophthalmol; 2016 Jun; 36(3):299-303. PubMed ID: 26272426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication.
    Ghosh S; O'Hare F; Lamoureux E; Vajpayee RB; Crowston JG
    Clin Exp Ophthalmol; 2012; 40(7):675-81. PubMed ID: 22394358
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reliability of fluorescein dye disappearance test in assessment of adults with nasolacrimal duct obstruction.
    Kashkouli MB; Mirzajani H; Jamshidian-Tehrani M; Pakdel F; Nojomi M; Aghaei GH
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):167-9. PubMed ID: 23503058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eyelid Changes Related to Meibomian Gland Dysfunction in Early Middle-Aged Patients Using Topical Glaucoma Medications.
    Kim JH; Shin YU; Seong M; Cho HY; Kang MH
    Cornea; 2018 Apr; 37(4):421-425. PubMed ID: 29227342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of nasolacrimal canal blockage on topical medications for glaucoma.
    Aritürk N; Oge I; Erkan D; Süllü Y; Sahin M
    Acta Ophthalmol Scand; 1996 Aug; 74(4):411-3. PubMed ID: 8883562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adherence to topical glaucoma medication during hospitalization.
    Yousuf SJ; Jones LS
    J Glaucoma; 2011 Dec; 20(9):573-6. PubMed ID: 21048511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acquired external punctal stenosis: etiology and associated findings.
    Kashkouli MB; Beigi B; Murthy R; Astbury N
    Am J Ophthalmol; 2003 Dec; 136(6):1079-84. PubMed ID: 14644218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nasolacrimal duct obstruction caused by topical epinephrine.
    Spaeth GL
    Arch Ophthalmol; 1967 Mar; 77(3):355-7. PubMed ID: 6019557
    [No Abstract]   [Full Text] [Related]  

  • 49. Conjunctival cicatrizing disease presenting with lacrimal obstruction.
    Satchi K; McNab AA
    Orbit; 2016 Dec; 35(6):321-323. PubMed ID: 27559621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adherence to topical glaucoma medications in Ethiopian patients.
    Tamrat L; Gessesse GW; Gelaw Y
    Middle East Afr J Ophthalmol; 2015; 22(1):59-63. PubMed ID: 25624675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug.
    Sasaki T; Miyashita H; Miyanaga T; Yamamoto K; Sugiyama K
    Jpn J Ophthalmol; 2012 May; 56(3):214-8. PubMed ID: 22411166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Patient satisfaction with topical ocular hypotensives.
    Kerr NM; Patel HY; Chew SS; Ali NQ; Eady EK; Danesh-Meyer HV
    Clin Exp Ophthalmol; 2013; 41(1):27-35. PubMed ID: 22594958
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Punctal occlusion and topical medications for glaucoma.
    Huang TC; Lee DA
    Am J Ophthalmol; 1989 Feb; 107(2):151-5. PubMed ID: 2913809
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Obstruction of lacrimal sac caused by topical epinephrine.
    Barishak R; Romano A; Stein R
    Ophthalmologica; 1969; 159(4):373-9. PubMed ID: 4986711
    [No Abstract]   [Full Text] [Related]  

  • 55. Anti-glaucoma medication exposure in pregnancy: an observational study and literature review.
    Razeghinejad MR; Nowroozzadeh MH
    Clin Exp Optom; 2010 Nov; 93(6):458-65. PubMed ID: 21182661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.
    Flach AJ
    Trans Am Ophthalmol Soc; 2008; 106():138-45; discussion 145-8. PubMed ID: 19277229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ocular Surface Disease and Glaucoma Medications: A Clinical Approach.
    Zhang X; Vadoothker S; Munir WM; Saeedi O
    Eye Contact Lens; 2019 Jan; 45(1):11-18. PubMed ID: 30199425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical features and management of keratoconjunctivitis associated with inadequate tear drainage.
    Gouvea L; Mimouni M; Alshaker S; Din N; Deangelis DD; Tucker N; Gill H; Slomovic AR; Chan CC
    Can J Ophthalmol; 2024 Jun; 59(3):e206-e212. PubMed ID: 37088101
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Utility of Cap Color and Bottle Characteristics for Topical Glaucoma Therapy.
    Marando CM; Seibold LK; SooHoo JR; Pantcheva MB; Ramulu PY; Kahook MY
    Ophthalmology; 2015 Dec; 122(12):2577-8. PubMed ID: 26077575
    [No Abstract]   [Full Text] [Related]  

  • 60. Obstruction of lacrimal puncta caused by topical epinephrine.
    Romano A; Barishak R; Stein R
    Ophthalmologica; 1973; 166(4):301-5. PubMed ID: 4709370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.